Clinical trials: Azacitidine
Acute Myeloid Leukemia, Acute Undifferentiated Leukemia
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
This phase I/II trial studies the safety, side effects, and best dose of decitabine in combination with fludarabine, cytarabine, filgrastim, and idarubicin (FLAG-Ida) and total body irradiation (TBI) followed by a donor stem cell…
- Conditions
- Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT06928662
- Testing
- Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Healthy
Effect of Food on the Pharmacokinetics of Decitabine/Tetrahydrouridine Combination Capsules in Healthy Adult Subjects
This study is to investigate the effect of a high fat meal on the pharmacokinetics of decitabine and THU in healthy adults when administered as a modified release formulation of the 2 drugs in combination.
- Trial name
- NCT04086238
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- EpiDestiny, Inc.
Tuberculosis, Pulmonary
Azacytidine During Anti-tuberculosis Therapy
Tuberculosis has been shown to make immune genes inaccessible and slows immune response The purpose of this research is to see if if azacitidine is safe and can return the ability of the body to resist tuberculosis (TB), a…
- Trial name
- AZA (NCT03941496)
- Testing
- Azacitidine Injection
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Andrew Dinardo
Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
This phase I trial tests the safety, side effects and best dose of NEXI-001 when given with decitabine and lymphodepleting chemotherapy in treating patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that…
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
- Trial name
- NCT06572631
- Testing
- Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001, Biospecimen Collection, Bone Marrow Aspiration
- Volunteers
- healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Healthy
Pharmacokinetics of Asacol 2.4 g/Day and Lialda 2.4 g/Day in Healthy Volunteers
This study evaluated pharmacokinetics of 5-ASA and N-Ac-5-ASA associated with each of 3 regimens of oral mesalamine 2.4 g/day (Lialda 2.4 g/day 2 x 1.2 g every 24 hours, Asacol® 6 x 400 mg every 24 hours, or Asacol 2 x 400 mg…
- Trial name
- NCT00751699
- Testing
- Asacol, Lialda
- Where
- United States
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Warner Chilcott
Thrombocytopenia, Isolated, Stem Cell Transplant Complications
AZA Combined With NAC for PIT After HSCT
Prolonged isolated thrombocytopenia (PIT) that is refractory to conventional treatments has remained a critical complication after allogeneic hematopoietic cell transplantation since decades years ago.
- Trial name
- NCT05126004
- Testing
- Azacitidine, N Acetyl L Cysteine
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Myelocytic Leukemia, Myelodysplastic Syndromes
Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Allo - hematopoietic stem cell transplantation is currently the only way to cure myelodysplastic syndrome /acute leukemia . The existing experimental results showed that decitabine and 5-azacytidine up-regulated the expression of…
- Trial name
- NCT01809392
- Testing
- decitabine
- Where
- China
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Soochow University
Healthy
To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males
This is an open-label, randomized, single-dose per period, two-period, crossover study to evaluate the relative bioavailability of decitabine and tetrahydrouridine ingested as a modified-release combination formulation compared…
- Trial name
- NCT05816356
- Testing
- Decitabine, Tetrahydrouridine
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- EpiDestiny, Inc.
Acute Myeloid Leukemia
Safety and Efficacy of Venetoclax in Combination With Azacitidine and HA Regimen in the Treatment of AML in the Elderly
This is a prospective phase II, single-arm clinical study that plans to enroll 45 patients aged 60 years or older with primary AML diagnosed after April 1, 2023.The purpose of this trial is to evaluate the efficacy of Venetoclax…
- Trial name
- NCT05949762
- Testing
- Venetoclax in Combination With Azacitidine and HA Regimen
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- ZePing Zhou
Healthy
Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects
To study the pharmacokinetic profiles of decitabine and tetrahydrouridine (THU) from 3 modified release formulations in healthy subjects.
- Trial name
- EPI01 (NCT03828084)
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- EpiDestiny, Inc.
Immunotherapy, Refractory Leukemia
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML
This is an single center, single arm, phase 3 study to evaluate efficacy and safety of PD-1 Inhibitor combined with DNA methyltransferase inhibitor Azacytidine and HAG regimen for patients with relapsed and refractory acute…
- Conditions
- Immunotherapy, Refractory Leukemia, Relapsed Adult AML, Acute Myeloid Leukemia
- Trial name
- NCT04722952
- Testing
- Visilizumab
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Soochow University
Hodgkin's Lymphoma
A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma
This study is a Phase II single-center clinical trial designed to assess the efficacy, safety, and tolerability of pembrolizumab in combination with the 7-day regimen of azacitidine for the treatment of relapsed/refractory HL.
- Trial name
- NCT05355051
- Testing
- Azacytidine, Pembrolizumab
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
AML (Acute Myelogenous Leukemia)
Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade
The combination of azacitidine and venetoclax is currently considered a therapeutic strategy innovative in AML through the addition of new compounds (triplet therapies), including inhibitors of the immune checkpoint inhibitors.
- Trial name
- NCT06874257
- Testing
- Laboratory tests and in vitro studies
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Cocaine Addiction
Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction
This study aims at testing for the impact of glutamatergic changes on drug craving in cocaine addiction, and to evaluate the effects of n-acetylcysteine (n-AC) on both glutamate homeostasis and craving using a randomized…
- Trial name
- CoGlu (NCT02626494)
- Testing
- N-Acetylcystein
- Where
- Switzerland
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Psychiatric University Hospital, Zurich